{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-25-027032","form_type":"8-K","ticker":"RCKT","cik":"0001281895","company_name":"ROCKET PHARMACEUTICALS, INC.","filed_at":"2025-07-24T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.575171+00:00","generated_at":"2026-05-18T02:04:11.761365+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Rocket Pharma restructures, cuts headcount 30%, delays FA/PKD programs; cash runway to Q2 2027","bullets":["Headcount reduction of ~30% and 12-month cash burn reduction of ~25% as part of corporate reorganization.","Pipeline focus on AAV cardiovascular programs (Danon, PKP2-ACM, BAG3-DCM) and KRESLADI for severe LAD-I.","Cash runway extended into Q2 2027; excludes any potential proceeds from Priority Review Voucher for KRESLADI.","Fanconi Anemia (RP-L102) and Pyruvate Kinase Deficiency (RP-L301) programs delayed; FDA OK for RP-L102 no longer expected in 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-25-027032","json":"https://secwatch.observer/filing/0001140361-25-027032.json","markdown":"https://secwatch.observer/filing/0001140361-25-027032.md","text":"https://secwatch.observer/filing/0001140361-25-027032.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1281895/000114036125027032/0001140361-25-027032-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1281895/000114036125027032/ef20052552_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T02:04:11.761365+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}